November 10, 2011
Daiichi Sankyo announced on November 8 that it had signed a basic agreement with Kyorin Pharmaceutical Co., Ltd. for the development and marketing of imidafenacin, a treatment for overactive bladder (OAB; marketed as Uritos in Japan). Imidafenacin was discovered by...read more